Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H van der HELM

Showing results (11-20 of 16) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 16 results.
Plos One|October 20, 2010
Genetic variation of the Fc gamma receptor 3B gene and association with rheumatoid arthritisRute B Marques, Mohamed M Thabet, Stefan J White, et al.
Annals of the Rheumatic Diseases|March 7, 2013
Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritisParawee Suwannalai, Karin Britsemmer, Rachel Knevel, et al.
Leukemia Research|May 1, 2013
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blastsL H van der Helm, N J G M Veeger, M van Marwijk Kooy, et al.
Arthritis Care & Research|June 28, 2012
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityJeffrey R Curtis, Annette H van der Helm-van Mil, Rachel Knevel, et al.
British Journal of Haematology|October 11, 2011
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programmeLieke H van der Helm, Canan Alhan, Pierre W Wijermans, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association StudiesElena López-Isac, Jose-Ezequiel Martín, Shervin Assassi, et al.
Pageof 2

Showing results (11-20 of 16) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
Plos One|October 20, 2010
Genetic variation of the Fc gamma receptor 3B gene and association with rheumatoid arthritisRute B Marques, Mohamed M Thabet, Stefan J White, et al.
Annals of the Rheumatic Diseases|March 7, 2013
Low-avidity anticitrullinated protein antibodies (ACPA) are associated with a higher rate of joint destruction in rheumatoid arthritisParawee Suwannalai, Karin Britsemmer, Rachel Knevel, et al.
Leukemia Research|May 1, 2013
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blastsL H van der Helm, N J G M Veeger, M van Marwijk Kooy, et al.
Arthritis Care & Research|June 28, 2012
Validation of a novel multibiomarker test to assess rheumatoid arthritis disease activityJeffrey R Curtis, Annette H van der Helm-van Mil, Rachel Knevel, et al.
British Journal of Haematology|October 11, 2011
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programmeLieke H van der Helm, Canan Alhan, Pierre W Wijermans, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|April 26, 2016
Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association StudiesElena López-Isac, Jose-Ezequiel Martín, Shervin Assassi, et al.
Pageof 2